

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2013		September 30, 2013	
	International	Total	International	Total
	Net Sales	Net Sales	Net Sales	Net Sales
Net sales, as reported	\$ 14,643	\$ 57,641	\$ 46,107	\$ 174,506
Currency impact as compared to prior period	459	459	905	905
Net sales, excluding the impact of foreign currency	<u>\$ 15,102</u>	<u>\$ 58,100</u>	<u>\$ 47,012</u>	<u>\$ 175,411</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012⁽¹⁾	September 30, 2013	September 30, 2012⁽¹⁾
Operating Income from Continued Operations				
Operating (loss) income, as reported	\$ (232,559)	\$ (2,263)	\$ (258,966)	\$ 33
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	197	48	499	144
BioMimetic inventory write-down	979	—	979	—
Total	<u>1,176</u>	<u>48</u>	<u>1,478</u>	<u>144</u>
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	112	416	803	624
Transition costs - OrthoRecon divestiture	11,244	—	13,867	—
Due diligence, transaction and transition costs - BioMimetic & Biotech ⁽²⁾	1,680	—	10,623	—
Total	<u>13,036</u>	<u>416</u>	<u>25,293</u>	<u>624</u>
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	625	764	2,172	1,134
<i>Other Reconciling Items:</i>				
BioMimetic impairment charges	206,249	—	206,249	—
Restructuring charges	—	—	—	430
Operating (loss) income, as adjusted	<u>\$ (11,473)</u>	<u>\$ (1,035)</u>	<u>\$ (23,774)</u>	<u>\$ 2,365</u>
Operating (loss) income, as adjusted, as a percentage of net sales	<u>(19.9)%</u>	<u>(2.0)%</u>	<u>(13.6)%</u>	<u>1.5%</u>

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) For the nine months ended September 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012 ⁽¹⁾	September 30, 2013	September 30, 2012 ⁽¹⁾
Net Income				
Loss from continuing operations before taxes, as reported	\$ (172,584)	\$ (6,667)	\$ (205,654)	\$ (7,731)
<i>Pre-tax impact of reconciling items:</i>				
Restructuring charges	—	—	—	430
Inventory step-up amortization	197	48	499	144
Distributor conversion and non-competes	737	1,180	2,975	1,758
Non-cash interest expense on 2017 Convertible Notes	2,187	687	6,456	687
Derivatives mark-to-market adjustment	2,000	(2,330)	3,000	(2,330)
Loss on interest rate swap termination	—	1,769	—	1,769
Transition costs - OrthoRecon divestiture	11,244	—	13,867	—
Due diligence, transaction and transition costs - BioMimetic & Biotech ⁽²⁾	1,680	—	10,623	—
BioMimetic impairment and other charges and CVR mark-to-market adjustments	141,081	—	146,921	—
Write-off of deferred financing fees associated with Senior Credit Facility and 2014 Convertible Notes	—	2,721	—	2,721
Gain on previously held investment in BioMimetic	—	—	(7,798)	—
Loss from continuing operations before taxes, as adjusted	(13,458)	(2,592)	(29,111)	(2,552)
Benefit for income taxes, as reported	\$ (48,084)	\$ (2,579)	\$ (60,697)	\$ (2,700)
Restructuring charges	—	—	—	164
Inventory step-up amortization	74	19	192	56
Distributor conversion and non-competes	278	461	1,152	691
Non-cash interest expense on 2017 Convertible Notes	868	268	2,541	268
Derivatives mark-to-market adjustment	781	(910)	1,181	(910)
Loss on interest rate swap termination	—	691	—	691
Transition costs - OrthoRecon divestiture	4,392	—	5,417	—
Due diligence, transaction and transition costs - BioMimetic & Biotech	468	—	2,471	—
BioMimetic impairment and other charges and CVR mark-to-market adjustments	35,973	—	35,973	—
Write-off of deferred financing fees associated with Senior Credit Facility and 2014 Convertible Notes	\$ —	\$ 1,063	\$ —	\$ 1,063
Benefit for income taxes, as adjusted	\$ (5,250)	\$ (987)	\$ (11,770)	\$ (677)
Effective tax rate, as adjusted	39.0%	38.1%	40.4%	26.5%
Net loss from continuing operations, as adjusted	\$ (8,208)	\$ (1,605)	\$ (17,341)	\$ (1,875)
Net (loss) income from discontinued operations, as reported	\$ (5,520)	\$ (1,251)	\$ 6,041	\$ 4,963
Reconciling items related to discontinued operations, net of tax ⁽³⁾	\$ 3,737	\$ 1,949	\$ (4,797)	\$ 5,532
Net (loss) income, as adjusted	\$ (9,991)	\$ (907)	\$ (16,097)	\$ 8,620

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

- (2) For the nine months ended September 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.
- (3) For the three month periods ended September 30, 2013 and 2012, amounts include the after tax impacts of \$0.5 million and \$1.7 million of U.S. governmental inquiries and DPA costs, \$0.3 million and \$0.4 million of amortization of distributor non-competes, \$5.2 million and \$0 of transaction costs associated with the OrthoRecon divestiture, respectively. For the nine month periods ended September 30, 2013 and 2012, amounts include \$2.3 million and \$6.6 million of U.S. governmental inquiries and DPA costs, \$1.1 million and \$0.6 million of amortization of distributor non-competes, \$7.9 million and \$0 of transaction costs associated with the OrthoRecon divestiture, a gain of \$19.4 million and \$0 for estimated product liability insurance recoveries, and \$0 and \$1.2 million of restructuring charges, respectively.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended September 30, 2013		Three Months Ended September 30, 2012 ⁽¹⁾	
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net loss from continuing operations	\$ (124,500)	\$ (8,208)	\$ (4,088)	\$ (1,605)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
Diluted net loss from continuing operations	\$ (124,500)	\$ (8,208)	\$ (4,088)	\$ (1,605)
Diluted net (loss) income from discontinued operations	(5,520)	(1,783)	(1,251)	698
Diluted net loss	(130,020)	(9,991)	(5,339)	(907)
Basic shares	46,418	46,418	38,907	38,907
Dilutive effect of stock options and restricted shares	N/A	N/A	NA	N/A
Dilutive effect of convertible notes	N/A	N/A	N/A	N/A
Diluted shares	46,418	46,418	38,907	38,907
Net loss from continuing operations per share, diluted	\$ (2.68)	\$ (0.18)	\$ (0.11)	\$ (0.04)
Net (loss) income from discontinued operations per share, diluted	\$ (0.12)	\$ (0.04)	\$ (0.03)	\$ 0.02
Net loss per share, diluted	\$ (2.80)	\$ (0.22)	\$ (0.14)	\$ (0.02)

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

	Nine Months Ended September 30, 2013		Nine Months Ended September 30, 2012 ⁽¹⁾	
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net loss from continuing operations	\$ (144,957)	\$ (17,341)	\$ (5,031)	\$ (1,875)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
Diluted net loss from continuing operations	\$ (144,957)	\$ (17,341)	\$ (5,031)	\$ (1,875)
Diluted net income from discontinued operations	6,041	1,244	4,963	10,495
Diluted net (loss) income	(138,916)	(16,097)	(68)	8,620
Basic shares	44,721	44,721	38,706	38,706
Dilutive effect of stock options and restricted shares	N/A	N/A	NA	N/A
Dilutive effect of convertible notes	N/A	N/A	N/A	N/A
Diluted shares	44,721	44,721	38,706	38,706
Net loss from continuing operations per share, diluted	\$ (3.24)	\$ (0.39)	\$ (0.13)	\$ (0.05)
Net income from discontinued operations per share, diluted	\$ 0.14	\$ 0.03	\$ 0.13	\$ 0.27
Net (loss) income per share, diluted	\$ (3.11)	\$ (0.36)	\$ —	\$ 0.22

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012 ⁽¹⁾	September 30, 2013	September 30, 2012 ⁽¹⁾
Net Income per Diluted Share				
Net loss from continuing operations, as reported, per diluted share	\$ (2.68)	\$ (0.11)	\$ (3.24)	\$ (0.13)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
Effect of convertible notes on diluted shares	N/A	N/A	N/A	N/A
Inventory step-up amortization	0.00	0.00	0.01	0.00
Distributor conversion and non-competes	0.01	0.02	0.04	0.03
Non-cash interest expense on 2017 Convertible Notes	0.03	0.01	0.09	0.01
Derivatives mark-to-market adjustment	0.03	(0.04)	0.04	(0.04)
Loss on interest rate swap termination	—	0.03	—	0.03
BioMimetic impairment and other charges and CVR mark-to-market adjustments	2.25	—	2.47	—
Write-off of deferred financing fees associated with Senior Credit Facility and 2014 Convertible Notes	—	0.04	—	0.04
Transition costs - OrthoRecon divestiture	0.15	—	0.19	—
Due diligence, transaction and transition costs - BioMimetic & Biotech	0.03	—	0.18	—
Gain on previously held investment in BioMimetic	—	—	(0.17)	—
Net loss from continuing operations, as adjusted, per diluted share ⁽²⁾	\$ (0.18)	\$ (0.04)	\$ (0.39)	\$ (0.05)

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating

adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

Wright Medical Group, Inc.
Reconciliation of Free Cash Flow
(dollars in thousands--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
Net cash provided by operating activities	\$ (34)	\$ 16,639	\$ 5,721	\$ 57,752
Capital expenditures	(12,777)	(4,718)	(22,512)	(13,291)
Free cash flow	\$ (12,811)	\$ 11,921	\$ (16,791)	\$ 44,461